1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Ionis Pharmaceuticals Inc (IONS) Files 10-K for the Fiscal Year Ended on December 31, 2019

March 02, 2020 | About:

Ionis Pharmaceuticals Inc (NASDAQ:IONS)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis Pharmaceuticals Inc has a market cap of $7.28 billion; its shares were traded at around $51.72 with a P/E ratio of 24.98 and P/S ratio of 8.98. GuruFocus has detected 2 severe warning signs with Ionis Pharmaceuticals Inc. .

For the last quarter Ionis Pharmaceuticals Inc reported a revenue of $494.0 million, compared with the revenue of $192.1 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.1 billion, an increase of 87.3% from last year. For the complete 30-year financial data, please go here.. For the last five years Ionis Pharmaceuticals Inc had an average revenue growth rate of 36.4% a year.

The reported diluted earnings per share was $2.08 for the year, an increase of 0.5% from previous year. The Ionis Pharmaceuticals Inc enjoyed an operating margin of 32.59%, compared with the operating margin of -10.23% a year before. The 10-year historical median operating margin of Ionis Pharmaceuticals Inc is -24.68%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, Ionis Pharmaceuticals Inc has the cash and cash equivalents of $2.5 billion, compared with $278.8 million in the previous year. The long term debt was $785.0 million, compared with $633.0 million in the previous year. The interest coverage to the debt is 7.5. Ionis Pharmaceuticals Inc has a financial strength rank of 6 (out of 10).

At the current stock price of $51.72, Ionis Pharmaceuticals Inc is traded at 24.7% discount to its historical median P/S valuation band of $68.72. The P/S ratio of the stock is 8.98, while the historical median P/S ratio is 12.26. The stock lost 28.47% during the past 12 months.

Directors and Officers Recent Trades:

  • SVP & General Counsel Patrick R. O'neil sold 3,882 shares of IONS stock on 02/10/2020 at the average price of $59.6. The price of the stock has decreased by 13.22% since.

For the complete 20-year historical financial data of IONS, click here.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)